Bio-Technology/NNP General/NNP Corp./NNP received/VBD tenders/NNS for/IN 97.9/CD %/NN of/IN its/PRP$ 7.5/CD %/NN convertible/JJ senior/JJ subordinated/VBN notes/NNS due/JJ April/NNP 15/CD ,/, 1997/CD ,/, and/CC 96/CD %/NN of/IN its/PRP$ 11/CD %/NN convertible/JJ senior/JJ subordinated/VBN debentures/NNS due/JJ March/NNP 1/CD ,/, 2006/CD ./.
In/IN exchange/NN offers/NNS that/WDT *T*-1/-NONE- expired/VBD Friday/NNP ,/, holders/NNS of/IN each/DT $/$ 1,000/CD *U*/-NONE- of/IN notes/NNS will/MD receive/VB $/$ 250/CD *U*/-NONE- face/NN amount/NN of/IN Series/NNP A/NNP 7.5/CD %/NN senior/JJ secured/VBN convertible/JJ notes/NNS due/JJ Jan./NNP 15/CD ,/, 1995/CD ,/, and/CC 200/CD common/JJ shares/NNS ./.
For/IN each/DT $/$ 1,000/CD *U*/-NONE- face/NN amount/NN of/IN debentures/NNS ,/, holders/NNS received/VBD $/$ 250/CD *U*/-NONE- of/IN Series/NNP B/NNP 11/CD %/NN senior/JJ secured/VBN convertible/JJ notes/NNS due/JJ Oct./NNP 15/CD ,/, 1998/CD ,/, and/CC 200/CD common/JJ shares/NNS ./.
Bio-Technology/NNP ,/, a/DT New/NNP York/NNP maker/NN of/IN genetically/RB engineered/VBN products/NNS for/IN human/NN and/CC animal/NN health/NN care/NN ,/, said/VBD 0/-NONE- it/PRP made/VBD the/DT exchange/NN offer/NN *-1/-NONE- to/TO reduce/VB its/PRP$ interest/NN payments/NNS ./.

